In contrast, isoform-specific inhibitors leverage oncogenic dependencies in particular cancers: α-selective alpelisib demonstrates efficacy in PIK3CA-mutant HR+/HER2− breast cancer by selectively blocking mutant p110α, while δ-selective idelalisib exploits B cell receptor pathway reliance in lymphoid malignancies. Here, PIK3CA is linked to cancer.